Biochemistry, Genetics and Molecular Biology
DNA Damage
100%
Polo-Like Kinase
95%
Genome Instability
94%
Cancer Cell
88%
Cell Cycle
63%
Homologous Recombination
62%
DNA Damage Response
50%
DNA Repair
49%
Kinase
40%
Phosphotransferase
40%
DNA Damage Checkpoint
38%
Cyclin E1
36%
Cisplatin
35%
DNA Replication
35%
BRCA1
33%
BRCA2
33%
S Phase
31%
Dynamics
30%
Poly ADP Ribose Polymerase
28%
Anaphase-Promoting Complex
27%
Gene Expression
25%
P53
25%
Epidermal Growth Factor Receptor
25%
Cytotoxicity
23%
Cell Cycle Checkpoint
22%
Oncogene
22%
Poly ADP Ribose Polymerase
20%
RAD51
19%
Immunocompetent Cell
19%
Chromosome Instability
17%
Cell Cycle Progression
16%
Cell Cycle Arrest
15%
Messenger RNA
15%
Wee1
15%
Carcinogenesis
14%
Quantitative Proteomics
14%
DNA Synthesis
14%
Oxidative Phosphorylation
13%
MUC1
13%
Helicase
13%
Chromatin Remodeling
13%
Mitosis
13%
Tumor Suppressor Gene
12%
Genetic Screen
12%
Genetics
11%
Mouse
10%
Drive
10%
Ataxia Telangiectasia and Rad3 Related
10%
Transcription
9%
Interphase
9%
Medicine and Dentistry
Neoplasm
44%
Cancer Cell
44%
Malignant Neoplasm
37%
Ovarian Cancer
36%
Cisplatin
29%
Homologous Recombination
25%
Molecular Imaging
21%
Genomic Instability
20%
PARP Inhibitor
19%
DNA Repair
17%
DNA Damage
16%
Breast Cancer
15%
DNA Damage Response
15%
Xenograft
15%
Testis Cancer
13%
BRCA1
11%
Disease
10%
Gamma Urogastrone
10%
Treatment Response
10%
Radiation Therapy
9%
Rectum Cancer
9%
Neoadjuvant Therapy
9%
Signal Transduction
8%
Triple Negative Breast Cancer
8%
S Phase
8%
Epidermal Growth Factor Receptor
8%
Oncogene
8%
Cancer Therapy
8%
Tumor Cell
8%
Patient Selection
8%
Head and Neck Squamous Cell Carcinoma
8%
BRCA2
7%
Diffuse Large B-Cell Lymphoma
7%
Colorectal Cancer
7%
Biological Marker
7%
Metastatic Carcinoma
7%
Cancer Model
7%
Personalized Medicine
7%
Recombination Repair
7%
Cytotoxicity
7%
Cell Cycle
7%
Radiosensitivity
6%
Oncology
6%
Genetic Screen
6%
Carboplatin
6%
Head and Neck Cancer
6%
cGAS-STING signaling pathway
6%
Immunocompetent Cell
6%
Beta1 Integrin
6%
Antibody-Drug Conjugate
6%
Keyphrases
Polo-like Kinase 1 (PLK1)
30%
DNA Damage
26%
CGAS-STING
23%
Cancer Cells
18%
Genomic Instability
17%
Inflammatory Pathways
17%
Carboplatin
13%
PARylation
13%
Cisplatin Sensitivity
13%
Ovarian Cancer
13%
Wee1 Inhibitors
13%
CtIP
13%
Homologous Recombination
12%
Cisplatin
10%
Cancer Treatment
10%
Mitosis
9%
DNA Damage Response
9%
Replication Stress
9%
Cyclic GMP-AMP Synthase (cGAS)
8%
Cyclin E1
8%
Sigma Phase
8%
DNA Repair
8%
Replication Speed
8%
In Cancer
8%
High-grade Serous Ovarian Cancer (HGSOC)
8%
Overexpression
7%
Chromosomal Instability
7%
BRCA1, BRCA2
7%
Homologous Recombination Defect
7%
Re-resection
7%
Breast Cancer Susceptibility Gene 1 (BRCA1)
7%
Tumor Cells
6%
Checkpoint Control
6%
Mammalian Cells
6%
Power Supply
6%
Protein Phosphatase
6%
Cell Cycle Re-entry
6%
Volume 14
6%
EGFR Inhibition
6%
Concurrent Chemoradiotherapy
6%
RNA Stabilization
6%
Head-and-neck Squamous Cell Carcinoma (HNSCC)
6%
Novel Therapeutics
6%
FIGNL1
6%
Therapeutic Potential
6%
Rb Protein
6%
Feedback Network
6%
Mitotic Phosphorylation
6%
Magnesium
6%
Testicular Cancer
6%
